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Myeloid-derived suppressor cells (MDSC) induced during neoplasia display potent pro-tumorigenic activities. Tumor-
derived factors influence MDSC development, yielding monocytic and granulocytic subsets. In contrast to monocytic
MDSC, little is known about how granulocytic MDSC develop. We demonstrated that tumor-derived G-CSF drives
granulocytic MDSC formation, thus providing new insights into myeloid-tumor biology.
Despite significant progress in cancer
diagnosis and treatment, many patients
still succumb to invasive or metastatic
disease. One potentially important reason
for limited therapeutic efficacy reflects the
overall therapeutic strategy. Current para-
digms for understanding the biology of
disease are heavily focused on the “cell-
intrinsic” (genetic and epigenetic) events
that govern neoplastic development.
1
However, it is now well-regarded that
tumor cell interactions with the host are
critical to achieve full malignant capabi-
lity,
2,3 suggesting that this host-dependent
arm of the neoplastic process has important
implications for prognosis and therapy.
Compelling studies reveal that myeloid-
derivedsuppressorcells(MDSC), arelatively
newly discovered leukocyte population
induced in both cancer patients and
animal models, promote neoplastic pro-
gression through multiple mechanisms,
including immune suppression and angio-
genesis.
2,4,5 MDSC are found systemically
in the blood and secondary lymphoid
tissues, as well as locally at sites of disease
activity. They constitute heterogeneous
populations of monocytic and granulocytic
cells reflecting a continuum of differentia-
tion stages. In mouse models, MDSC
subsets can be distinguished from other
regulatory myelo-monocytic populations
on the basis of unique phenotypic profiles.
MonocyticMDSCareCD11b
+Ly6C
hiLy6G
-
(or CD11b
+Gr-1
lo), whereas granulocytic
MDSC are CD11b
+Ly6C
loLy6G
+ (or
CD11b
+Gr-1
hi).
2,6 Although much atten-
tion has been dedicated to unraveling
mechanisms by which the MDSC subsets
mediate immune suppression and tumor
progression, a larger gap remains in our
understanding of the mechanisms that
initiate their development. Enhancing
our understanding of the molecular basis
for MDSC subset development could
facilitate the identification of new bio-
markers or therapeutic targets to improve
responses to immunotherapy.
It is thought that the inappropriate
secretion of hematopoietic growth factors
by tumors can alter normal myelopoiesis
and lead to the accumulation of dysfunc-
tional myeloid populations, like MDSC.
As noted earlier, MDSC fall into mono-
cytic and granulocytic subsets, although
both have been shown to be equally
immunosuppressive.
6 It turns out that
granulocytic cell types comprise a major
component of the MDSC response;
2,6 yet,
the underlying reasons for this remain
unclear. Although a number of tumor-
derived factors (TDF) have been linked to
diverse elements of MDSC biology,
namely VEGF, GM-CSF, IL-1β, IL-6,
IL-10 or PGE2,
2,4 none have been rigor-
ously tested to explain their connection
with the granulocytic MDSC response.
Since the overall MDSC response is a
manifestation of deregulated myelopoiesis,
we hypothesized that the inappropriate
production of certain hematopoietic
growth factors, like granulocyte-colony
stimulating factor (G-CSF), is an under-
explored key initiator of granulocytic
MDSC development.
Ordinarily, endogenous G-CSF regu-
lates granulopoiesis and has a vital role in
neutrophil mobilization in response to
diverse insults.
7 Exogenous G-CSF is also
important to overcome neutropenia
caused by various anti-neoplastic treat-
ments. However, G-CSF paradoxically can
elicit adverse effects and inhibit innate
and adaptive immunity.
8 The notion that
G-CSF may not always be beneficial to
the host is also supported by the findings
that G-CSF is aberrantly expressed in
human neoplasia.
9 But how would
G-CSF fit into the pathway of MDSC
generation? The connection between
G-CSF and MDSC would likely converge
at the level of STAT3 based on the
knowledge that G-CSF signaling is
strongly STAT3-dependent
7 and that
elevated STAT3 activity is important for
the accumulation of MDSC
2 (Fig.1).
Thus, we took a mechanistic approach to
dissect a potentially new role of G-CSF in
myeloid-tumor biology.
10
First, we observed abundant amounts
of G-CSF in several, but not all mouse
tumor models tested. Interestingly, G-CSF
production directly correlated with gra-
nulocytic MDSC generation. To test the
hypothesis that G-CSF production and the
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granulocytic MDSC response are causally
linked, three systematic in vivo approaches
were then taken: (1) RNA interference to
silence G-CSF production in a G-CSF-
expressing tumor; (2) ectopic overexpres-
sion of G-CSF in a non-G-CSF-expressing
tumor; and (3) direct injection of recom-
binant G-CSF protein. Overall, we found
that G-CSF loss-of-function decreased
granulocytic MDSC generation, while
G-CSF gain-of-function (via transfection
or direct injection of protein) had the
opposing impact.
10 In addition to its
effects on granulocytic MDSC burden,
we observed that tumor-derived G-CSF
significantly increased tumor growth rate.
By cell depletion studies, we determined
that the G-CSF-tumor effect was largely
due to the induced granulocytic MDSC
response.
These data are consistent with a new
cyclical paradigm that the neoplastic
process influences granulocytic MDSC
development through the secretion of
G-CSF, and that the accumulation of
granulocytic MDSC in turn further nur-
tures tumor growth/progression (Fig.1).
Therefore, the identification of myeloid-
reactive targets, such as G-CSF, provides
the rationale to target G-CSF for pro-
gnostic or therapeutic purposes in appro-
priate subsets of patients where such
cytokine levels are demonstrable. Monitor-
ing changes in sera/plasma G-CSF levels,
along with other clinicopathologic para-
meters, may define a “biomarker signature”
of disease status. Therapeutic approaches
that target granulocytic MDSC-initiating
TDF may offer additional ways to
abrogate MDSC-mediated mechanisms
of tumor progression to enhance the
efficacy of immune-based interventions.
Such approaches would be akin to those
used for TNF blockade (e.g., Remicade
1)
in patients with certain autoimmune
disorders or VEGF blockade (e.g.,
Avastin
1) in patients with certain solid
cancers to reduce disease-associated cyto-
kine levels below a ‘pathologic threshold’.
It is also noteworthy that the admini-
stration of G-CSF protein led to the
induction of granulocytic-like MDSC,
which strongly recapitulated the pheno-
typic, functional and molecular charac-
teristics observed with tumor-induced
granulocytic MDSC.
10 These data argue
that high concentrations of circulating
G-CSF can impair myeloid cell develop-
ment/differentiation, leading to granulo-
cytic MDSC formation. Thus, the
development of granulocytic MDSC in
response to G-CSF exposure may also have
important implications in non-neoplastic
settings and explain, in part, the basis of
immune suppression or tolerance under
such clinical situations.
8
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Figure1. Granulocytic MDSC development via G-CSF-dependent mechanisms. Aberrant myelo-
poiesis from bone marrow progenitors (i.e., granulocyte-macrophage/GMP) is initiated by TDF,
many of which function through STAT3. We propose that aphysiologic levels of tumor-derived
G-CSF constitute a relevant myelopoietic growth factor, which triggers STAT3 activation in GMP
ensuing G-CSF receptor engagement. Activated STAT3 then translocates to the nucleus where it
binds to specific elements of myelopoietic target genes that in turn alter normal myeloid cell
differentiation, perhaps skewing development in the direction of granulocytic MDSC. Several STAT3
target genes have been previously described.
2 A few examples of relevant TDF, as well as
mechanisms of granulocytic and monocytic MDSC-mediated tumor progression are shown.
Such TDF may influence MDSC in multiple ways, including how MDSC function or mobilize to sites
of pathologic challenges.
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